Golimumab
| Evidence Level: L4 | Predicted Indications: 5 |
Table of Contents
Golimumab: From Rheumatoid Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Golimumab is a fully human anti-TNF-α monoclonal antibody used in inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis). The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, but the supporting evidence is thin and partly contradictory — 3 clinical trials (none targeting this indication specifically) and 6 publications, including case reports of anti-TNF therapy triggering vasculitis rather than treating it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (derived from literature evidence in this pack; no UK licence text available — see Data Gaps) |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available from regulatory sources in this evidence pack (flagged as a High-severity data gap). Based on the literature retrieved, golimumab is a fully human anti-TNF-α IgG1κ monoclonal antibody, administered subcutaneously or intravenously, approved for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
TNF-α is a key mediator of vascular inflammation, so anti-TNF therapy is mechanistically plausible for rheumatoid vasculitis, an extra-articular complication of rheumatoid arthritis. However, the literature in this pack cuts both ways: one case report notes that severe extra-articular manifestations such as rheumatoid vasculitis have become less frequent since anti-TNF agents entered practice, while a separate case report describes Takayasu’s arteritis — a large-vessel vasculitis — arising during anti-TNF treatment (so-called paradoxical vasculitis). This means the mechanistic direction is not settled: anti-TNF therapy may suppress or, in some patients, precipitate vasculitic disease.
Separately, two other TxGNN-predicted indications in this pack (inflammatory spondylopathy and polyarticular juvenile idiopathic arthritis, ranks 3 and 5) are supported by much stronger evidence (L1, multiple completed Phase 3 RCTs), but these largely overlap with golimumab’s already-established anti-TNF indication class rather than representing genuine repurposing — worth noting for context when prioritising follow-up.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01579006 | N/A | Completed | 184 | Observational study of tocilizumab (not golimumab) in RA patients with inadequate DMARD response; evaluates general practice patterns and safety, not designed for rheumatoid vasculitis. |
| NCT05696106 | N/A | Unknown | 750,000 | Large-scale study of the risk of incident immune-mediated inflammatory diseases (including vasculitis) in patients on biologics/immunosuppressants; a safety-signal study, not efficacy evidence for golimumab in this indication. |
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Perioperative immunosuppressant management in rheumatology patients undergoing shoulder arthroplasty; unrelated to vasculitis treatment efficacy and not yet recruiting. |
None of the three trials directly evaluates golimumab for rheumatoid vasculitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31491879 | 2019 | Network Meta-Analysis | International Journal of Molecular Sciences | Compared five TNF inhibitors, including golimumab, on radiographic joint destruction in RA across 36 RCTs; general TNFi efficacy data, not vasculitis-specific. |
| 23557513 | 2013 | Review | BMC Medicine | General review of biologic therapies for autoimmune/rheumatologic disease; background context only. |
| 27591827 | 2017 | Cohort | Seminars in Arthritis and Rheumatism | Cohort study on end-stage renal disease frequency in RA patients; not specific to vasculitis or golimumab. |
| 29075910 | 2018 | Case Report | Rheumatology International | Golimumab-treated RA patient with pyoderma gangrenosum/pyogenic arthritis presenting as severe sepsis; notes rheumatoid vasculitis incidence has fallen, but not disappeared, since anti-TNF agents were introduced. |
| 22999907 | 2013 | Case Report | Joint Bone Spine | Two cases of Takayasu’s arteritis (large-vessel vasculitis) arising during anti-TNF therapy — a paradoxical safety signal relevant to this indication. |
| 23252659 | 2013 | Case Report | Ocular Immunology and Inflammation | Behçet disease-associated uveitis successfully treated with golimumab (off-label), illustrating use beyond approved indications in other immune-mediated inflammatory disease. |
UK Market Information
No UK marketing authorisations are recorded in this evidence pack (market status: Not marketed, 0 licences on file). Prescribers should consult the current SmPC/BNF entry for golimumab (marketed elsewhere as Simponi) directly for authorised indications and formulations, as this cannot be confirmed from the data available here.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for golimumab in rheumatoid vasculitis is Level L4 (mechanism-only), no trial directly targets this indication, and the literature itself contains a conflicting safety signal — anti-TNF therapy has been reported to cause vasculitis (e.g. Takayasu’s arteritis) in some patients, which undercuts the case for repurposing pending closer scrutiny.
To proceed, the following is needed:
- TFDA/MHRA SmPC warnings and contraindications (Blocking gap — required before any safety assessment)
- Confirmed mechanism of action data from DrugBank (High-priority gap)
- A dedicated clinical study or case series evaluating golimumab specifically in rheumatoid vasculitis, rather than general RA cohorts
- Clarification of the paradoxical vasculitis risk signal (Takayasu’s arteritis, PMID 22999907) before considering further evaluation stages
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.